Dihydropyridine-sensitive Ca2+ channels and inositol phospholipid metabolism in ethanol physical dependence.
D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / Q000494:pharmacology; D000437:Alcoholism / Q000378:metabolism* / Q000503:physiopathology; D000818:Animals; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism*; D004095:Dihydropyridines; D006892:Hydroxydopamines / Q000494:pharmacology; D066298:In Vitro Techniques; D007295:Inositol Phosphates / Q000378:metabolism*; D007473:Ion Channels / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects / Q000503:physiopathology; D009568:Nitrendipine / Q000494:pharmacology; D016627:Oxidopamine; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D013403:Sugar Phosphates / Q000378:metabolism*; D014649:Vas Deferens / Q000503:physiopathology
D004095:Dihydropyridines; D006892:Hydroxydopamines; D007295:Inositol Phosphates; D007473:Ion Channels; D011725:Pyridines; D013403:Sugar Phosphates; D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; C038806:1,4-dihydropyridine; D016627:Oxidopamine; D009568:Nitrendipine